Chemokine (C-C Motif) Ligand 20, a Potential Biomarker for Graves' Disease, Is Regulated by Osteopontin

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Li, Xiaoli ^a,b   Qi, Yicheng ^a,b   Ma, Xinran ^b,c   Huang, Fengjiao ^a   Guo, Hua ^a   Jiang, Xiaohua ^a   Hong, Jie ^a   Lin, Dongping ^b   Cui, Bin ^a,b   Ning, Guang ^a,b   Xu, Lingyan ^b,c   Wang, Shu ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; BIOLOGICAL MARKER; CYTOKINE ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN RECEPTOR; INTERLEUKIN 17; LIOTHYRONINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPONTIN; OSTEOPONTIN ANTIBODY; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HUMAN; IMMUNOREGULATION; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADOLESCENT; ADULT; BASE SEQUENCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL20; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OSTEOPONTIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 84878057038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064277     Document Type: Article

References (42)

1. Lichiardopol C, Mota M, (2009) The thyroid and autoimmunity. Rom J Intern Med 47: 207-15.
2. Mao C, Wang S, Xiao Y, Xu J, Jiang Q, et al. (2011) Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol 186: 4734-4743.
3. Hot A, Miossec P, (2011) Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 70: 727-732.
4. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, et al. (2010) Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62: 2876-2885.
5. Di Cesare A, Di Meglio P, Nestle FO, (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339-1350.
6. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, et al. (2009) Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58: 1302-1311.
7. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O'Shea JJ, (2011) T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 32: 395-401.
8. Nanba T, Watanabe M, Inoue N, Iwatani Y, (2009) Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease. Thyroid 19: 495-501.
9. Guo T, Huo Y, Zhu W, Xu F, Liu C, et al. (2012) Genetic association between IL-17F gene polymorphisms and the pathogenesis of Graves' Disease in the Han Chinese population. Gene 512: 300-304.
10. Rossi DL, Vicari AP, Franz-Bacon K, McClanahan TK, Zlotnik A, (1997) Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta. J Immunol 158: 1033-1036.
11. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, et al. (2009) C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10: 514-523.
12. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, et al. (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204: 2803-2812.
13. Ghannam S, Dejou C, Pedretti N, Giot JP, Dorgham K, et al. (2011) CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions. J Immunol 186: 1411-1420.
14. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, et al. (2009) C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10: 514-523.
15. Murugaiyan G, Mittal A, Weiner HL, (2008) Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 181: 7480-7488.
16. Chen G, Zhang X, Li R, Fang L, Niu X, et al. (2012) Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum 62: 2900-2908.
17. Wang KX, Denhardt DT, (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19: 333-345.
18. Ohshima S, Kobayashi H, Yamaguchi N, Nishioka K, Umeshita Sasai M, et al. (2002) Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum 46: 1094-1101.
19. Sakata M, Tsuruha JI, Masuko-Hongo K, Nakamura H, Matsui T, et al. (2001) Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 28: 1492-1495.
20. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K, (2003) Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol 136: 125-129.
21. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H, (2002) Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 168: 2096-2099.
22. D'Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, et al. (2005) Two single-nucleotide polymorphisms in the 50 and 30 ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52: 539-547.
23. Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, et al. (2005) Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 54: 1254-1262.
24. Xu L, Ma X, Wang Y, Li X, Qi Y, et al. (2011) The expression and pathophysiological role of osteopontin in Graves' disease. J Clin Endocrinol Metab 96(11): E1866-1870.
25. Koguchi Y, Kawakami K, Uezu K, Fukushima K, Kon S, et al. (2003) High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 167: 1355-1359.
26. Renkl AC, Wussler J, Ahrens T, Thoma K, Kon S, et al. (2005) Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 106: 946-955.
27. O'Regan AW, Hayden JM, Berman JS, (2000) Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 68: 495-502.
28. Lampe MA, Patarca R, Iregui MV, Cantor H, (1991) Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol 147: 2902-2906.
29. Iizuka J, Katagiri Y, Tada N, Murakami M, Ikeda T, et al. (1998) Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest 78: 1523-1533.
30. Hirata T, Osuga Y, Takamura M, Kodama A, Hirota Y, et al. (2010) Recruitment of CCR6-expressing Th17 cells by CCL 20 secreted from IL-1 beta-, TNF-alpha-, and IL-17A-stimulated endometriotic stromal cells. Endocrinology 151: 5468-5476.
31. Meares GP, Ma X, Qin H, Benveniste EN, (2012) Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 60: 771-781.
32. Giachelli CM, (1998) NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 141: 1083-1093.
33. Zheng W, Li R, Pan H, He D, Xu R, et al. (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60: 1957-65.
34. Lin YH, Yang-Yen HF, (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signal-ing pathway. J Biol Chem 276: 46024-46030.
35. Le Y, Zhou Y, Iribarren P, Wang J, (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1: 95-104.
36. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P, (2007) Role of chemokines in endocrine autoimmune diseases. Endocr Rev 28: 492-520.
37. Xu G, Nie H, Li N, Zheng W, Zhang D, et al. (2005) Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 115: 1060-1067.
38. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, et al. (2006) Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 93: 1226-1231.
39. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, et al. (2007) Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 92: 1485-1490.
40. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, et al. (2010) CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 95: E413-420.
41. Inoue M, Shinohara ML, (2011) Intracellular osteopontin (iOPN) and immunity. Immunol Res 49: 160-172.
42. Standal T, Borset M, Sundan A, (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26: 179-184.